Despite numerous clinical trials in ovarian, fallopian tube, and peritoneal cancer, questions persist regarding the optimal use of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) [1, 2]. Here, VEGFA is linked to peritoneum cancer.